Malin Corporation | MLC - Cash And Equivalent


Malin Corporation reported EUR62.1M in Cash and Equivalent for its fiscal semester ending in December of 2024.





Cash And Equivalent Change Date
Akebia Therapeutics USD 159.25M 3.71M Sep/2026
Alaunos Therapeutics USD 124K 230K Jun/2026
ALKERMES USD 631.31M 119.78M Sep/2026
Avita Medical AUD 9.14M 1.1M Jun/2026
Dianthus Therapeutics USD 55.69M 54.86M Sep/2026
Eurofins Scientific SE EUR 791.2M 37.9M Dec/2025
Ionis Pharmaceuticals USD 350.06M 1.57B Jun/2026
IQVIA Holdings USD 2.25B 340M Sep/2026
Lonza CHF 719M 188M Dec/2025
Malin Corporation EUR 62.1M 26.4M Dec/2024
Moderna USD 1.2B 528M Sep/2026
Organon & Co USD 1.46B 323M Sep/2026
Revvity USD 592.8M 430.14M Sep/2026
Tectonic Therapeutic USD 227.07M 9.83M Jun/2026
Viatris USD 1.79B 902.7M Sep/2026
Xeris Pharmaceuticals USD 131.08M 9.33M Sep/2026